Sotatercept is an investigational drug that belongs to a class of molecules known as activin receptor type IIA ligand traps. It works by binding and neutralizing certain proteins in the body that regulate the growth and development of cells, particularly red blood cells. Sotatercept is being studied as a potential treatment for various hematologic disorders, including anemia and beta-thalassemia. Preliminary research suggests that sotatercept may help increase red blood cell production and improve symptoms in patients with these conditions. Clinical trials are ongoing to further evaluate the safety and effectiveness of sotatercept in treating hematologic disorders.